ICER Is Weighing Early Research Consulting Work With Pharma

16 Oct 2018
News

Jessica Merrill @Jessicaemerrill Jessica.merrill@informa.com

Executive Summary

The drug value assessment organization said it is considering whether or not to move forward with a program to consult pharmaceutical manufacturers on early research, a move that could raise questions about the group's independence.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Clinical Trials Health Technology Assessment Pricing Debate

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS124080

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS124080

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

ICER Is Weighing Early Research Consulting Work With Pharma

News

Executive Summary

Related Content

Praluent Pricing: Collaboration With ICER Sets A New Standard

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert